Novo reports positive Phase III REDEFINE 1 results for CagriSema
The post hoc assessment showed that 67.8% of participants receiving CagriSema achieved early responder status by week eight.
A leading resource for the Pharmaceutical industry since 2002
The post hoc assessment showed that 67.8% of participants receiving CagriSema achieved early responder status by week eight.
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance